Research & deveLOPMent
Phosplatin Therapeutics has engaged in research and development activities with collaborators in fourteen countries.
Our relationships within the pharmaceutical industry, with U.S. and European universities, and with contract research organizations, cover Clinical Development, translational research activities, as well as manufacturing and analytical method development for PT-112, our lead agent in oncology therapeutics.
PT-112 is the subject of two orphan drug designations by the US FDA, and is in clinical trials in the UNited States and china.
To learn more about the Ongoing U.S. Phase I study in solid tumors, please visit the link below:
To learn more about the U.S. Phase I / II Study in multiple myeloma, please visit the link below:
To learn more about the U.S. Phase Ib / IIA combination Study with the pd-l1 Checkpoint Inhibitor avelumab in Solid Tumors, please visit the link below: